Cetuximab Biosimilar, N297A Mutant. The research grade cetuximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Cetuximab biosimilar CHO stable cell line is available for licensing to manufacture...
Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody. Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein.The research grade bevacizumab biosimilar protein is for research use only (RUO). Recombinant human...
Bevacizumab Biosimilar, N297A Mutant. Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein.The research grade bevacizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype...
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant. Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein.The research grade bevacizumab biosimilar protein is for research use only...
Recombinant Anti-DYKDDDDK-Tag Mouse Fab Fragment (Clone M2.1). In vivo grade recombinant DYKDDDDK-Tag monoclonal antibodies with various isotypes; alternative of the monoclonal FLAG M2 antibody; for in vitro and in vivo studies including protein purification; low...
In vivo Grade Recombinant Anti-DYKDDDDK-Tag Human IgG1 Monoclonal Antibody (clone M2.1). In vivo grade recombinant DYKDDDDK-Tag monoclonal antibodies with various isotypes; alternative of the monoclonal FLAG M2 antibody; for in vitro and in vivo studies...
GST-Tag Monoclonal Antibody. Conditions of optimal GST-Tag antibody performance should be determined experimentally by the investigator.
GFP Monoclonal Antibody. Conditions of optimal GFP / RFP antibody performance should be determined experimentally by the investigator.
DYKDDDDK-Tag Monoclonal Antibody. Conditions of optimal DYKDDDDK-Tag antibody performance should be determined experimentally by the investigator.
RFP Monoclonal Antibody. Conditions of optimal RFP antibody performance should be determined experimentally by the investigator.
